§ Federal grant opportunity · PAR-25-081
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health is accepting applications for National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required). The deadline is January 7, 2027 and the published award range is $500K.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- January 7, 2027
- Award range
- $500K
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Education, Health
- Opportunity number
- PAR-25-081
Program overview
Through this Notice of Funding Opportunity, the National Cancer Institute (NCI) seeks research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before January 7, 2027, allowing time for registration and validation.
Related grant opportunities
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.